Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GIV-IN PV phase 3 trial of givinostat versus hydroxyurea in high-risk JAK2V617F-positive polycythemia vera
MOH_2024-02-04_013231Phase 3Active, not recruiting
- Sponsor
- Italfarmaco
- Start
- Jan 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in polycythemia vera (PV) comparing Givinostat with Hydroxyurea (2 arms). Primary endpoint: Efficacy, safety, and tolerability at Week 48. Started Jan 2024; status: active, not recruiting.
02
Drugs
givinostathydroxyurea
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on MOH_2024-02-04_013231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-02-04_013231.